These 2 FTSE growth stocks jumped 8% and 4.5% today!

Two FTSE companies reported upbeat buying and selling updates as we speak (15 July). These had been Experian (LSE: EXPN) and Genus (LSE: GNS). As I sort, they’re up 4.5% and practically 9%, respectively.

Credit score checker Experian from the FTSE 100 has notched a 52-week — and all-time — excessive above 4,000p. Nevertheless, animal genetics agency Genus from the FTSE 250 stays 60% beneath a 2021 peak, regardless of rising 55% 12 months up to now.

Clearly, buyers favored what they noticed from this pair as we speak. Let’s discover why these shares are spiking.

FTSE 100

After as we speak’s rise, Experian’s market cap now sits above £37bn. That’s greater than well-known Footsie companies like Tesco (£27bn) and BT (£19bn).

The corporate is among the world’s largest client credit score reporting companies. It tracks the borrowing historical past of each people and companies, together with loans, bank cards, mortgage funds, defaults, and extra. Experian then makes use of this information to generate credit score stories utilized by lenders and different monetary establishments. 

At the moment’s buying and selling replace lined the three months to the tip of June. Total, international income progress at fixed foreign money was up a formidable 12% (8% natural progress). 

The progress was broad-based throughout all areas. North America is the agency’s largest market, accounting for 67% of gross sales, so it was encouraging to see income leap 10% there. Within the UK and Eire, income was 8% larger, because it was in Latin America. 

Nevertheless, at fixed alternate charges, Latin America surged 17%, and now accounts for extra income than the UK and Eire. I’m actually bullish on the area, as lots of of hundreds of thousands of shoppers there are starting to entry monetary providers by means of their smartphones. 

Consequently, Experian seems to have a sizeable long-term alternative in Latin America. It additionally highlighted sturdy quarterly progress in Australia, New Zealand, India and Southern Europe. 

For the total 12 months ending March 2026, administration continues to count on complete income progress of 9% to 11%. Strong stuff. 

FTSE 250

Turning to Genus, the agency has launched an unaudited buying and selling replace for its fiscal 12 months that ended 30 June.

As talked about, it specialises in animal genetics, serving to farmers breed pigs and cattle that develop quicker, resist illness, and ship higher yields (milk, for instance). 

Genus operates by means of two major divisions: PIC (pig genetics) and ABS (dairy and beef cattle). Each of those carried out effectively, with PIC delivering double-digit underlying progress in adjusted working revenue, whereas ABS got here in forward of expectations within the second half. 

Collectively, they’re anticipated to drive adjusted pre-tax revenue of no less than £68m, consistent with expectations. 

Nevertheless, in April, the US well being regulator (FDA) gave the inexperienced mild for Genus’s gene-edited pig — one which’s proof against a significant illness — for use within the American meals provide. This triggered a £3.7m web milestone receipt, boosting adjusted pre-tax revenue to no less than £72m.

Silly takeaway

I feel each shares are value contemplating. However buyers ought to know that Experian now trades at 31 occasions forecast earnings. If progress is available in mild in future quarters, which might occur in recessionary occasions, the inventory would possibly dump.

As for Genus, it must get the disease-resistant pig gene edit previous different regulators (failure to take action is a threat). Nonetheless, I wrote in Might that I assumed the inventory was “set for a roaring restoration“.

I nonetheless suppose this, and have since purchased some shares.